Abstract
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecular chaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60, the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotective but a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examples of specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicate a pathogenic role for HSP60 but also its potential as a biomarker with applications for diagnosis, assessing prognosis and response to treatment, as well as for preventing and treating CVD.
Keywords: Chaperonin, heat shock protein 60, cardiomyocytes, heart failure, cardiovascular disease, atherosclerosis, apoptosis, microRNAs (miRs), diabetes, Atrial fibrillation
Current Pharmaceutical Design
Title: Heat Shock Protein-60 and Risk for Cardiovascular Disease
Volume: 17 Issue: 33
Author(s): Manfredi Rizzo, Alberto J.L. Macario, Everly Conway de Macario, Ioanna Gouni-Berthold, Heiner K. Berthold, Giovam Battista Rini, Giovanni Zummo and Francesco Cappello
Affiliation:
Keywords: Chaperonin, heat shock protein 60, cardiomyocytes, heart failure, cardiovascular disease, atherosclerosis, apoptosis, microRNAs (miRs), diabetes, Atrial fibrillation
Abstract: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecular chaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60, the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotective but a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examples of specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicate a pathogenic role for HSP60 but also its potential as a biomarker with applications for diagnosis, assessing prognosis and response to treatment, as well as for preventing and treating CVD.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, J.L. Macario Alberto, Conway de Macario Everly, Gouni-Berthold Ioanna, K. Berthold Heiner, Battista Rini Giovam, Zummo Giovanni and Cappello Francesco, Heat Shock Protein-60 and Risk for Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220981
DOI https://dx.doi.org/10.2174/138161211798220981 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Random Walks on Biomedical Networks
Current Proteomics Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy
Current Drug Delivery Detection and Treatment of Alcohol-Induced Hypertension
Current Hypertension Reviews Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Fibrosis, Enzymatic and Non-Enzymatic Cross-Links in Hypertensive Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Increased Content of Free Phenolic Compounds and Antioxidant Activity of Grape Pomace Cultivated with Three Different β-glucosidase Fungi Producers
Current Bioactive Compounds A Review of Macrolide Treatment of Atherosclerosis and Abdominal Aortic Aneurysms
Current Drug Targets - Infectious Disorders Analogy of Cardiac and Renal Complications in Essential Hypertension and Aged SHR or L-NAME/SHR
Medicinal Chemistry The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology